What rilzabrutinib is and why reversibility matters in BTK inhibition

Rilzabrutinib is a reversible, non-covalent inhibitor of Bruton’s tyrosine kinase (BTK) developed by Sanofi, and its mechanism of action is the central scientific argument for its differentiation in a crowded kinase inhibitor field. Unlike first-generation covalent BTK inhibitors — which permanently modify their target until new BTK protein is synthesised — rilzabrutinib binds and unbinds BTK in an equilibrium-driven manner, a property with meaningful implications for tolerability, drug-drug interactions, and suitability for autoimmune indications requiring long-term continuous dosing.

BTK is a non-receptor tyrosine kinase that occupies a pivotal node in the B-cell receptor (BCR) signalling cascade. When a B cell’s antigen receptor is engaged, BTK is recruited and activated, propagating signals that drive B-cell proliferation, survival, and ultimately antibody secretion. In oncology, this pathway has been exploited since the approval of ibrutinib for chronic lymphocytic leukaemia by the U.S. Food and Drug Administration. The insight that the same pathway drives pathological B-cell activity in autoimmune disease — where autoreactive B cells produce antibodies against self-antigens — has opened a new therapeutic frontier.

The practical consequence of reversible binding in an autoimmune context is that the drug’s pharmacodynamic effect tracks more closely with its plasma concentration profile. This may reduce the cumulative kinase off-target burden that has been associated with some adverse effects seen with irreversible agents — including atrial fibrillation and bleeding — though direct comparative data in ITP specifically are still accumulating from ongoing trials.

Immune thrombocytopenia: the disease context driving BTK interest

Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by immune-mediated destruction of platelets and suppression of platelet production, resulting in a platelet count typically below 100 × 10⁹/L and a clinically significant risk of bleeding. The condition affects both children and adults, with the adult form often following a chronic, relapsing course that requires repeated or sustained therapeutic intervention — making the tolerability and convenience of any treatment a critical determinant of real-world use.

The immunopathology of ITP involves multiple converging mechanisms. Autoreactive B cells produce IgG autoantibodies — predominantly targeting platelet surface glycoproteins GPIIb/IIIa and GPIb/IX — which opsonise platelets for phagocytic clearance by splenic and hepatic macrophages via Fc-gamma receptor engagement. Simultaneously, cytotoxic T cells directly lyse platelets and megakaryocytes, and regulatory T-cell dysfunction impairs peripheral tolerance. This multi-mechanistic pathology explains why no single therapeutic target has proven universally effective, and why agents addressing upstream immune dysregulation — such as BTK inhibitors acting on B-cell activation — are attracting significant research interest, as noted in reviews published by The New England Journal of Medicine.

“In ITP, autoreactive B cells producing anti-platelet antibodies represent an upstream pathological driver — inhibiting BTK addresses this root cause rather than simply stimulating platelet production downstream.”

Current first-line management typically involves corticosteroids and intravenous immunoglobulin (IVIg), which provide rapid but often transient platelet count elevation. Patients who fail or become dependent on first-line therapy are candidates for second-line options, which historically included splenectomy and rituximab, and now increasingly include thrombopoietin receptor agonists (TPO-RAs) and, more recently, FcRn inhibitors. The heterogeneity of the patient population — in terms of disease duration, prior treatment history, and underlying immune endotype — creates a segmented market where mechanistically distinct agents can each find a clinical niche.

Sanofi’s Phase III programme and the clinical development rationale for rilzabrutinib in ITP

Sanofi’s decision to advance rilzabrutinib into Phase III evaluation for immune thrombocytopenia reflects both the strength of early-phase clinical signals and the company’s broader strategic commitment to immunology and haematology. The Phase III programme is designed to generate the pivotal efficacy and safety data required for regulatory submission, building on Phase I/II work that demonstrated platelet count responses and an acceptable tolerability profile in patients with ITP and other immune-mediated conditions.

The clinical development of rilzabrutinib in ITP is informed by the drug’s earlier investigation across multiple immune-mediated indications, including pemphigus vulgaris and immunoglobulin A nephropathy, where the reversible BTK inhibition mechanism has been explored for its potential to modulate B-cell-driven autoimmunity. This multi-indication strategy reflects a broader pharmaceutical industry trend — recognised in databases maintained by ClinicalTrials.gov — of developing mechanistically versatile immunology assets across a portfolio of related autoimmune diseases.

Phase III trial design in ITP typically involves a randomised, placebo-controlled or active-controlled study with a primary endpoint of sustained platelet count response — commonly defined as achieving a platelet count of ≥50 × 10⁹/L on a specified proportion of scheduled visits over a defined treatment period, without rescue medication. Secondary endpoints generally include bleeding event rates, patient-reported outcomes, and quality-of-life measures. The choice of comparator and patient population (newly diagnosed versus persistent versus chronic ITP) significantly influences the competitive positioning of any new agent, as standards of care differ across these subgroups according to guidelines from the American Society of Hematology.

The ITP competitive landscape: approved therapies and emerging challengers to rilzabrutinib

The ITP treatment landscape has undergone substantial transformation over the past decade, evolving from a field dominated by broad immunosuppression and splenectomy to one characterised by mechanistically targeted agents across multiple approved drug classes. Rilzabrutinib enters this landscape as a BTK inhibitor competing not only with other investigational BTK inhibitors but also with a growing set of approved second- and third-line options that have already demonstrated regulatory viability.

Among approved agents, the TPO-RAs — eltrombopag (Novartis/GSK) and romiplostim (Amgen) — have established themselves as the dominant second-line oral and subcutaneous options respectively, with well-characterised efficacy and safety profiles accumulated over more than a decade of post-approval use. Their mechanism — stimulating the thrombopoietin receptor to increase platelet production — is entirely distinct from BTK inhibition, meaning rilzabrutinib and TPO-RAs could potentially be used in combination or in sequence rather than as direct substitutes.

The more recent approval of efgartigimod alfa (argenx) for ITP represents a different mechanistic approach: blocking the neonatal Fc receptor (FcRn) to accelerate IgG catabolism, thereby reducing circulating anti-platelet antibody titres. This mechanism overlaps conceptually with BTK inhibition in targeting the antibody-mediated arm of ITP pathology, making efgartigimod a closer competitive reference point for rilzabrutinib than TPO-RAs. Other FcRn inhibitors including rozanolixizumab and nipocalimab are in various stages of ITP development, intensifying this segment of the competitive landscape.

Patent intelligence and IP strategy in the BTK inhibitor space

The intellectual property landscape surrounding BTK inhibitors is one of the most densely contested in pharmaceutical patent strategy, reflecting the commercial success of ibrutinib and the subsequent wave of next-generation inhibitor programmes from major oncology and immunology players. For rilzabrutinib specifically, Sanofi’s IP estate covers both the compound itself and its application across multiple autoimmune indications — a layered protection strategy that is standard practice for large-molecule and small-molecule assets with multi-indication potential.

Patent filings in the BTK inhibitor space span multiple categories: composition-of-matter patents covering the core chemical scaffold; method-of-use patents for specific disease indications including ITP; formulation patents; and combination therapy patents covering rilzabrutinib in combination with other immunosuppressive or platelet-modulating agents. As data from organisations such as WIPO illustrate, the volume of BTK-related patent applications has grown substantially since ibrutinib’s approval, with non-covalent inhibitor scaffolds representing an increasingly prominent share of recent filings as the field pivots toward autoimmune applications.

For drug discovery teams and IP professionals tracking this space, the key intelligence questions include: the expiry timeline of Sanofi’s core rilzabrutinib composition-of-matter patents; the breadth of method-of-use coverage for ITP specifically; whether any third-party patents present freedom-to-operate risks for Sanofi’s manufacturing or formulation processes; and the patent positions of competing non-covalent BTK inhibitors such as fenebrutinib (Roche) and tolebrutinib (Sanofi’s own MS-focused programme) that share structural or mechanistic features.

Monitoring the rilzabrutinib patent estate through an AI-native intelligence platform enables teams to receive automated alerts on new filings, track prosecution status across jurisdictions, and benchmark Sanofi’s IP position against competitors — capabilities that are directly available through PatSnap’s life sciences intelligence platform. With over 2 billion data points spanning more than 120 countries, PatSnap Eureka provides the breadth of coverage needed to map the full global BTK inhibitor IP landscape.